Evidence map›Paper›PMID 42227958›Full record

ArticleUrologia2026

Outcomes of Rezūm therapy in young men: A multi-center study.

Sagi Shprits, Mario Bitar, Omar Buksh, Abbas Hammoud, Naeem Bhojani, Bilal Chughtai, Kevin C Zorn, Luca Cindolo, Giovanni Ferrari, Katherine Lajkosz and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sagi ShpritsDivision of Urology, Department of Surgery, University of Toronto, ON, Canada.
Mario BitarDivision of Urology, Department of Surgery, University of Toronto, ON, Canada.ORCID 0009-0006-2867-9723
Omar BukshDivision of Urology, Department of Surgery, University of Toronto, ON, Canada.
Abbas HammoudAmerican University of Beirut, Lebanon.
Naeem BhojaniDivision of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada.
Bilal ChughtaiPlainview Hospital, Smith Institute of Urology, No0rthwell Health, Syosset, NY, USA.
Kevin C ZornBPH Canada, Prostate Surgical Institute, Montreal, QC, Canada.
Luca CindoloUrology Department, Hesperia Hospital, CUrE Group, Modena, Italy.
Giovanni FerrariUrology Department, Hesperia Hospital, CUrE Group, Modena, Italy.
Katherine LajkoszDepartment of Biostatistics, University Health Network, Toronto, ON, Canada.
Dean EltermanDivision of Urology, Department of Surgery, University of Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study is to evaluate the outcomes of the Rezūm procedure in men aged 50 years or younger, focusing on changes in urinary symptoms and quality of life.

methodsA prospective registry was created as part of the International Rezūm Registry database at two high-volume centers. The study reviewed data from patients monitored between April 2019 and August 2024. All patients aged 50 years or younger had their baseline medical and BPH history recorded, which included uroflowmetry measurements (Qmax and PVR) and validated questionnaires such as the International Prostate Symptom Score (IPSS), IPSS Quality of Life (QoL), Benign Prostatic Hyperplasia Impact Index (BPHII) and International Index of Erectile Function-15 (IIEF-15). Data were collected at baseline and at 3, 6, and 12 months following the procedure.

resultsFourteen patients were included, with a mean age of 49.6 years (SD 1.05). The mean baseline prostate volume was 54.3 cc (SD: 22.0). At baseline, the mean IPSS was 24.3 ± 5.9, which significantly improved to 10.5 ± 5.8 at 6 months and 11.6 ± 5.4 at 12 months. The IPSS QoL score improved from 4.8 ± 0.9 at baseline to 2.4 ± 1.7 at 12 months. Qmax increased from 7.9 ± 4.5 mL/s to 17.8 ± 6.1 mL/s at 12 months. PVR decreased from 197.6 ± 270.2 mL to 51 ± 77 mL at 12 months. IIEF scores showed no significant differences.

conclusionThe Rezūm procedure demonstrates significant efficacy in improving urinary symptoms and quality of life in men under 50.

Indexed as

Lower Urinary Tract SymptomsProstatic HyperplasiaQuality of LifeHumansMaleMiddle AgedProspective StudiesTreatment Outcomebenign prostatic hyperplasiafunctional outcomeslower urinary tract symptomsquality of lifewater vapor thermal therapy

Identifiers

PMID42227958
PMCPMC13672921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.